Absci Corporation Common Stock

Day range

$9.03 – $9.76

Open

$9.20

Prev close

$9.18

Volume

1.83M

Market cap

$1.58B

Shares out

171.61M

P/E

—

P/S

1009.24

P/B

6.40

P/FCF

—

ROE

-49.2%

ROA

-45.0%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Investor presentationAug 11, 2026

  On August 11, 2026, the Company released a presentation which includes certain internal pipeline program updates, which is available on the "News & Events" section of the Company's website. A copy of this presentation is filed as Exhibit 99.2 to this Current Report on Form 8-K.

• Public offeringJun 24, 2026

  The Shares will be sold to the purchasers at an offering price of $7.41 per share. The offering was made pursuant to the shelf registration statement on Form S-3 (File No. 333-289541) that was filed by the Company with the Securities and Exchange Commission ("SEC") on August 12, 2025, and declared effective by the SEC on August 22, 2025. The Company expects the offering to close on June 25, 2026.

• Clinical trial resultsJun 24, 2026

  On June 24, 2026, Absci Corporation issued a press release announcing Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201.

• Annual meeting resultsJun 5, 2026

  The Company's stockholders approved the Class II director nominees recommended for election in Proposal I at the Annual Meeting. The Company's stockholders voted for the Class II directors as follows: Prof Sir Menelas Pangalos, Ph.D. (74,118,258 For, 9,332,380 Withhold) and Daniel Rabinovitsj (69,590,534 For, 13,860,104 Withhold).

• Investor presentationMay 7, 2026

  On May 7, 2026, the Company released a presentation which includes certain internal pipeline program updates, which is available on the "News & Events" section of the Company's website. A copy of this presentation is filed as Exhibit 99.2 to this Current Report on Form 8-K.

Days to cover

7.5

Short interest

37.44M

Avg volume

4.98M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Global Drug Discovery AI Tools Market - Strategic Forecast 2026-2032 | Generative AI, Cloud Platforms, and Integrated R&D Workflows Create New Growth Opportunities
  positiveGlobeNewswire Inc.· Oct 5, 2026
• AI Poised to Reshape Blood Cancer Therapeutics as Investment Surges Past $2 Billion Across Leading Biotech and Pharma Players
  positiveGlobeNewswire Inc.· Aug 25, 2026
• The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It
  positiveBenzinga· Jun 16, 2026
• AMD Reveals A $6.5 Million Marvell Bet That's Already Soaring
  positiveBenzinga· May 13, 2026
• Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
  neutralGlobeNewswire Inc.· May 4, 2026